

5 March 2026

## Osteopore signs collaboration agreement with Tan Tock Seng Hospital for the development of a novel implant

### Highlights

- Osteopore signs collaboration agreement with Tan Tock Seng Hospital (TTSH) for the development of a novel implant to treat avascular necrosis (AVN) of the hip.
- The collaboration agreement (Agreement) is a follow-up from the National Health Innovation Centre Singapore Innovation-to-Industry (NHIC I2I) grant (announced 23 February 2026) and NHG Health's Centre for Medical Technologies & Innovations (CMTi) MedTech Grant received by TTSH (announced 9 September 2025), to co-develop this novel implant.
- It demonstrates the firm and collaborative intent of Osteopore and TTSH, and their commitment to the development of this implant.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: OSX; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants has signed a collaboration agreement with Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health in Singapore, for the development a novel implant used in the treatment of avascular necrosis (AVN) at the hip joint.

The collaboration agreement (Agreement) is a follow-up from the NHIC I2I and CMTi MedTech grants received by TTSH to co-develop this novel implant, announced earlier on 23 February



2026<sup>1</sup> and 9 September 2025<sup>2</sup> respectively. It demonstrates the firm and collaborative intent of Osteopore and TTSH, and their commitment to the development of this implant to address the clinical challenge of AVN at the hip joint.

**Key terms:**

- Period: 18 months ending in the 3<sup>rd</sup> quarter of 2027, unless terminated earlier, or extension required
- Intellectual Property (IP) ownership: Foreground IP will be jointly and equally owned by TTSH and Osteopore, with Osteopore as the lead in filing the joint IP
- Commercialisation of joint IP: Osteopore is granted an exclusive worldwide license to produce, sell and/or distribute, including any improvements or enhancements to the joint IP

AVN is a condition where blood supply is interrupted leading to necrosis of bone tissue. This condition predominantly occurs at the hip joint, although it can happen at other joints as well.

AVN of the hip can cause pain and discomfort. The conditions worsen over time, and without treatment, can result in the collapse of the bone at the hip joint. When that happens, total hip replacement (THR) becomes the most effective treatment. Approximately 10% of AVN cases result in THR. It is reported that there are between 20,000 and 30,000 new cases of AVN in the U.S. each year<sup>3</sup>.

---

<sup>1</sup> ASX announcement "OSX and TTSH secure additional funding for novel implant", 23 February 2026.

<sup>2</sup> ASX Announcement "OSX collaborates with TTSH to develop novel implant for AVN", 9 September 2025.

<sup>3</sup> <https://www.yalemedicine.org/conditions/avascular-necrosis-of-the-hip>

The total market opportunity of AVN treatment is projected to reach USD 10.2 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 8.5% between 2023 and 2030<sup>4</sup>. Growth drivers include: growing prevalence of AVN, increasing awareness of AVN, and earlier diagnosis.

**Commenting on the signing of the collaboration agreement, CEO Dr Yujing Lim said:**

"We are delighted to formalise the relationship with TTSH for the co-development of the implant to treat AVN at the hip joint, which is a growing clinical challenge.

"This method of open collaboration has the potential to align clinical needs with commercial potential, and we look forward to keep the market updated on the progress of this collaboration, as and when they become available", said Dr Lim.

**END**

*This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**

Executive Chairman

Osteopore Limited

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

---

<sup>4</sup> <https://www.verifiedmarketresearch.com/product/avasculer-necrosis-market/>



### About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.